Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early‐stage Alzheimer's disease-Reference-Cited by-同舟云学术

Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early‐stage Alzheimer's disease

Published:2014-03 Issue:2 Volume:10 Page:247-250
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Schneider Lon S.¹

Affiliation:

1. Keck School of MedicineUniversity of Southern CaliforniaLos AngelesCAUSA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2013.12.002

Reference13 articles.

1. U.S. Food and Drug Administration.Guidance for industry Alzheimer's disease: developing drugs for the treatment of early stage disease (FDA‐2013‐D‐0077) DRAFT.February 2013 [accessed 2013 June 30]. Available from:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf.

2. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

3. Revising the definition of Alzheimer's disease: a new lexicon

4. Draft guidance for industry on Alzheimer's disease: developing drugs for the treatment of early stage disease [transcript from FDA Webinar].March 28 2013. [accessed 2013 October 20]. Available from:http://www.fda.gov/training/guidancewebinars/ucm367786.htm.

5. Neuropathology of older persons without cognitive impairment from two community-based studies

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer’s Disease;Cells;2022-04-09

2. Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2022-01

3. Disease Stage-Associated Alterations in Learning and Memory through the Electroacupuncture Modulation of the Cortical Microglial M1/M2 Polarization in Mice with Alzheimer’s Disease;Neural Plasticity;2020-08-28

4. Traditional Oriental Medicines and Alzheimer’s Disease;Aging and disease;2019

5. The new β amyloid-derived peptide Aβ1–6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity;Neurobiology of Disease;2016-04